ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
1541
Classificação em ações
#19245
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biotechnology firm primarily... ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biotechnology firm primarily dedicated to advancing immunotherapeutic treatments for various cancers. At the forefront of its development pipeline is IMM01, a CD47-targeting molecule currently undergoing clinical investigation. This lead candidate is being evaluated for its efficacy across a broad spectrum of malignancies, including myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), classical Hodgkin lymphoma (cHL), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), head and neck squamous cell carcinomas (HNSCC), and colorectal cancer (CRC). Beyond its primary program, the company boasts a robust portfolio of experimental therapies. These comprise IMM0306, a bispecific CD47×CD20 molecule aimed at relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL); IMM2902, another bispecific agent combining CD47 and HER2 for solid tumors that are either HER2-positive or HER2-low expressing; and IMM2520, a bispecific CD47×PD-L1 molecule intended for various solid tumors. Further development efforts include IMM47, a humanized monoclonal antibody designed to target CD24 for cancer treatment; MM4701, a distinct bispecific molecule simultaneously engaging both CD47 and CD24; IMM2510, a bispecific "mAb-Trap" engineered to block both VEGF and PD-L1; IMM27M, a CTLA-4 antibody enhanced for ADCC activity; and IMM40H, a humanized IgG1 CD70 monoclonal antibody also featuring augmented ADCC activity. The company was established in 2015 and is headquartered in Shanghai, China.
Preço da ação
$0.38122017
Última sincronização: 2026-10-16
Valor de mercado
$159.74M
Variação (1 dia)
2.58%
Variação (1 ano)
-71.65%
País
CN
Negociar ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541)
Categoria
Healthcare
Capitalização de mercado de ImmuneOnco Biopharmaceuticals (Shanghai) Inc.(1541)
Valor de mercado: $159.74M
Em October 2026, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. tem uma capitalização de mercado de $159.74M. Isso faz com que ImmuneOnco Biopharmaceuticals (Shanghai) Inc. seja a 19245th empresa mais valiosa do mundo em termos de capitalização de mercado, de acordo com os nossos dados. A capitalização de mercado, também chamada de market cap, é o valor total de mercado das ações em circulação de uma empresa de capital aberto e é amplamente utilizada para medir o valor de uma empresa.
Histórico de capitalização de mercado de ImmuneOnco Biopharmaceuticals (Shanghai) Inc. de 2023 a 2026
1541 comparado com o topo de 5 mais populares stocks
| Preço para 1541 | Ativo B | Capitalização de mercado de B | Resultados | |
|---|---|---|---|---|
$12,492.52
$159.74M
|
$5.235T | +3,276,882.90% | ||
|
$11,956.46
$159.74M
|
$5.010T | +3,136,266.60% | ||
|
$9,927.88
$159.74M
|
$4.160T | +2,604,138.30% | ||
|
$9,472.18
$159.74M
|
$3.969T | +2,484,600.53% | ||
|
$6,753.74
$159.74M
|
$2.830T | +1,771,510.58% |
